Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity
Frontiers in Nutrition · 29.04.2024 · 11
DOI: 10.3389/fnut.2024.1398059 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Nutrition, online erschienen am 29.04.2024. Verfasst von Rafael Tamayo-Trujillo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigación Genética y Genómica, Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Obesity, a chronic global health problem, is associated with an increase in various comorbidities, such as cardiovascular disease, type 2 diabetes mellitus, hypertension, and certain types of cancer. The increasing global prevalence of obesity requires research into new therapeutic strategies. Glucagon-like peptide-1 receptor agonists, specifically semaglutide and liraglutide, designed for type 2 diabetes mellitus treatment, have been explored as drugs for the treatment of obesity. This minireview describes the molecular mechanisms of semaglutide and liraglutide in different metabolic pathways, and its mechanism of action in processes such as appetite regulation, insulin secretion, glucose homeostasis, energy expenditure, and lipid metabolism. Finally, several clinical trial outcomes are described to show the safety and efficacy of these drugs in obesity management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centro de Investigación Genética y Genómica, Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador.
- Universidad Espíritu Santo, Samborondón, Ecuador.
- Centro de Investigación de Salud Pública y Epidemiología Clínica (CISPEC), Universidad UTE, Quito, Ecuador.
Zitieren
APA
Tamayo-Trujillo, R., Ruiz-Pozo, V. A., Cadena-Ullauri, S., Guevara-Ramírez, P., Paz-Cruz, E., Zambrano-Villacres, R., Simancas-Racines, D., & Zambrano, A. K. (2024). Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. Frontiers in Nutrition, 11. https://doi.org/10.3389/fnut.2024.1398059
Vancouver
Tamayo-Trujillo R, Ruiz-Pozo VA, Cadena-Ullauri S, Guevara-Ramírez P, Paz-Cruz E, Zambrano-Villacres R, et al. Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. Frontiers in Nutrition. 2024;11. doi:10.3389/fnut.2024.1398059
BibTeX
@article{TamayoTrujillo2024,
author = {Tamayo-Trujillo, Rafael and Ruiz-Pozo, Viviana A and Cadena-Ullauri, Santiago and Guevara-Ramírez, Patricia and Paz-Cruz, Elius and Zambrano-Villacres, Raynier and Simancas-Racines, Daniel and Zambrano, Ana Karina},
title = {Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity},
journal = {Frontiers in Nutrition},
year = {2024},
volume = {11},
doi = {10.3389/fnut.2024.1398059}
}
EUVIMED